Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by First Interstate Bank

First Interstate Bank lifted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 27.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,901 shares of the medical research company’s stock after purchasing an additional 618 shares during the period. First Interstate Bank’s holdings in Thermo Fisher Scientific were worth $1,794,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. F M Investments LLC increased its stake in Thermo Fisher Scientific by 56.2% in the 3rd quarter. F M Investments LLC now owns 28,327 shares of the medical research company’s stock valued at $17,522,000 after purchasing an additional 10,193 shares in the last quarter. Chicago Partners Investment Group LLC increased its position in shares of Thermo Fisher Scientific by 40.8% in the third quarter. Chicago Partners Investment Group LLC now owns 1,001 shares of the medical research company’s stock valued at $577,000 after buying an additional 290 shares in the last quarter. Creative Capital Management Investments LLC boosted its position in shares of Thermo Fisher Scientific by 293.3% in the 3rd quarter. Creative Capital Management Investments LLC now owns 118 shares of the medical research company’s stock worth $73,000 after buying an additional 88 shares in the last quarter. Farther Finance Advisors LLC raised its position in Thermo Fisher Scientific by 16.4% during the third quarter. Farther Finance Advisors LLC now owns 3,824 shares of the medical research company’s stock worth $2,365,000 after acquiring an additional 539 shares during the last quarter. Finally, Dash Acquisitions Inc. lifted its stake in Thermo Fisher Scientific by 4.4% in the 3rd quarter. Dash Acquisitions Inc. now owns 30,901 shares of the medical research company’s stock valued at $19,114,000 after buying an additional 1,312 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $168,048.00. Following the completion of the sale, the executive vice president now owns 16,663 shares in the company, valued at approximately $9,333,946.08. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $168,048.00. Following the transaction, the executive vice president now directly owns 16,663 shares of the company’s stock, valued at approximately $9,333,946.08. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the completion of the sale, the chief executive officer now directly owns 121,192 shares of the company’s stock, valued at $67,175,513.68. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 12,300 shares of company stock valued at $6,831,268. Company insiders own 0.34% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on TMO. Stifel Nicolaus decreased their price objective on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. Bank of America upped their price objective on shares of Thermo Fisher Scientific from $600.00 to $675.00 and gave the company a “buy” rating in a research note on Monday, September 16th. Barclays cut their price target on Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a report on Wednesday, October 23rd. Raymond James raised their price objective on Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. Finally, Sanford C. Bernstein reduced their target price on Thermo Fisher Scientific from $625.00 to $620.00 and set a “market perform” rating on the stock in a research report on Thursday, October 24th. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus price target of $649.33.

Thermo Fisher Scientific Stock Up 2.1 %

Shares of TMO traded up $11.60 during mid-day trading on Friday, reaching $557.92. 1,459,815 shares of the stock traded hands, compared to its average volume of 1,349,276. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. The stock has a fifty day simple moving average of $599.39 and a 200 day simple moving average of $583.31. The firm has a market cap of $213.13 billion, a price-to-earnings ratio of 34.98, a P/E/G ratio of 3.61 and a beta of 0.79. Thermo Fisher Scientific Inc. has a 12-month low of $437.26 and a 12-month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The company had revenue of $10.60 billion during the quarter, compared to analysts’ expectations of $10.63 billion. During the same period in the prior year, the business posted $5.69 EPS. The business’s revenue was up .2% on a year-over-year basis. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current fiscal year.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.